Attana's collaboration with Prof. Salanti to develop a vaccine against COVID-19 elucidated by Life Science Sweden

As previously announced Attana supports Prof. Salanti and his team at the University of Copenhagen in their development of a vaccine against COVID-19. Earlier this week two of Attanas co-workers was in Prof. Salanti´s lab to support the initial experiments. This is further described (in Swedish) in Life Science Sweden med Kemivärlden. 

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com 
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact  sales@attana.com. 

Tags: